When studying gain-of-function (GOF) mutations in Shp2, which is the most common mutation found in JMML patients, we have previously focused on the downstream target phosphoinositide 3 kinase (PI3K). The gene discussed is PIK3CD; the disease is juvenile myelomonocytic leukemia.